Seagen tees up with Dutch I/O out­fit, en­gi­neers $700M deal for EGFR as­set

Amid re­ports that Mer­ck was go­ing to ac­quire Seagen, the Seat­tle com­pa­ny de­cid­ed to do its own M&A — se­cur­ing a back-heavy deal.

The an­ti­body-drug con­ju­gate pow­er­house an­nounced bright and ear­ly Mon­day that it would be shelling out as much as $700 mil­lion to LA­VA Ther­a­peu­tics, a Nether­lands-based gam­ma delta T cell en­gager biotech, for its EGFR-tar­get­ing drug can­di­date.

The can­di­date, called LA­VA-1223, is in an ad­vanced pre­clin­i­cal stage, LA­VA CEO Steve Hurly tells End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER